-
1 Comment
HeraMED Limited is currently in a long term uptrend where the price is trading 72.8% above its 200 day moving average.
From a valuation standpoint, the stock is 83.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 219.6.
Finally, its free cash flow fell by 22.0% to $-782K since the same quarter in the previous year.
Based on the above factors, HeraMED Limited gets an overall score of 2/5.
| Exchange | F |
|---|---|
| CurrencyCode | EUR |
| ISIN | AU0000028367 |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | 24M |
|---|---|
| PE Ratio | None |
| Target Price | None |
| Beta | 0.73 |
| Dividend Yield | None |
HeraMED Limited, a medical data and technology company, develops, manufactures, and sells home-based maternity monitoring technology in Australia and the United States. It also provides HeraBEAT, a medical device for fetal and maternal heart rate used by pregnant women; and HeraCARE, a remote fetal heart rate monitoring solution. The company has a collaboration agreement with Mayo Clinic for the development of its HeraCARE pregnancy management platform; and Broward Health for deployment of its HeraCARE to deliver care outcomes for pregnant mothers. HeraMED Limited was founded in 2011 and is based in Hawthorn East, Australia.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 1I4.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026